Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesHematology/Oncologymhn Donor Lymphocyte Infusion Coverage Update | Op…
    Ask Trek AI about this page
    CurrentmhnPolicy CP.MP.101

    Donor Lymphocyte Infusion

    Customize your policy alerts

    Sign up for mhn Policy CP.MP.101 alerts

    Get alerted when Policy CP.MP.101 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Medical necessity and coverage criteria for donor lymphocyte infusion following allogeneic hematopoietic stem cell transplantation for relapsed or high-risk hematologic malignancies; applies to non-Medicare health plans affiliated with the payer.

    Policy Summary
    Payermhn
    PolicyDonor Lymphocyte Infusion
    Policy CodePolicy CP.MP.101
    Change TypeNo material changes noted
    Effective Date
    Next Review Date
    Key ActionObtain prior authorization and submit clinical rationale with documentation of prior allogeneic HSCT and indication (relapse or high relapse risk).
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    40-60%GvHD after DLI
    70-80%CML remission rate
    15-20%AML remission chance
    2-5%Bone marrow aplasia
    CenteneOwner
    2016Copyright

    Coverage Criteria for Donor Lymphocyte Infusion (DLI)

    Initial and prophylactic DLI

    Covered when ALL of the following are met:

    Primary coverage indication: Recipient has previously undergone allogeneic hematopoietic stem cell transplantation (HSCT)
    Indication: DLI is being used to treat relapsed or refractory hematologic malignancy OR to decrease the risk of relapse (including conversion from mixed to full chimerism when there is risk of relapse)
    Chimerism consideration: DLI is not recommended for patients with full chimerism and should not be used solely to increase donor chimerism absent relapse risk

    Contraindications / Not supported

    Not supported / contraindicated when ANY of the following are present:

    Unsupported indications: Use of DLI for indications other than post-allogeneic HSCT to treat relapse or decrease relapse risk (e.g., genetic modification or ex vivo manipulation of donor lymphocytes)
    Active acute GvHD: Presence of grade 2 or higher acute graft-versus-host disease is a contraindication to DLIgrade >=2 acute GvHD

    Genetic modification or other ex vivo manipulation of donor lymphocytes for use in donor lymphocyte infusion (DLI) is not supported outside of an appropriate clinical trial setting and is not considered a covered indication under this policy.

    When state Medicaid coverage provisions conflict with this clinical policy, state Medicaid coverage provisions take precedence. Providers should consult the applicable state Medicaid manual for any specific coverage requirements or variations.

    Use of DLI solely to increase donor chimerism in a patient with no risk of relapse is not recommended and is considered not medically necessary. DLI should be reserved for treatment of relapsed or refractory hematologic malignancy or to decrease relapse risk when there is a clinical indication.

    Regimens and Indications Covered

    IndicationRegimen / RationaleCoverage Label
    Relapsed chronic myeloid leukemia (CML) after allogeneic HSCT
    DLI — high remission rates reported (complete remissions in 70–80% of patients); may be definitive therapy for relapsed CML
    Criteria: prior allogeneic HSCT and documented relapse; absence of contraindications such as grade ≥2 acute GvHD
    IndicationRegimen / RationaleCoverage Label
    Relapsed acute myeloid leukemia (AML) after allogeneic HSCT
    DLI often combined with chemotherapy to achieve an anti-tumor effect; remission induction probability with DLI alone ~15–20%
    Criteria: prior allogeneic HSCT and documented relapse; documentation of adjunct/prior chemotherapy may be relevant; absence of grade ≥2 acute GvHD
    IndicationRegimen / RationaleCoverage Label
    Relapsed multiple myeloma after allogeneic HSCT
    DLI may be used to stimulate a graft‑versus‑myeloma effect; reported response rates ~22–52%; NCCN notes DLI may be used to stimulate beneficial graft‑versus‑myeloma effect
    Criteria: prior allogeneic HSCT and relapsed disease; consider clinical trial status and absence of contraindications such as grade ≥2 acute GvHD
    IndicationRegimen / RationaleCoverage Label
    Conversion of mixed chimerism to full chimerism when there is risk of relapse
    DLI to convert mixed chimerism to full donor chimerism when clinically warranted; examples report conversion with clinical response in some patients
    Criteria: mixed chimerism (<90% donor cells) with clinical risk of relapse or evidence of impending relapse; prior allogeneic HSCT and no contraindicating active grade ≥2 acute GvHD

    Procedure and Billing Codes

    Referenced procedure codesmixed
    38215Transplant preparation of hematopoietic progenitor cells; cell concentration in plasma, mononuclear, or buffy coat layer.
    38242Allogeneic lymphocyte infusions.
    86950Leukocyte transfusion
    S2150Bone marrow or blood-derived stem cells (peripheral or umbilical), allogeneic or autologous, harvesting, transplantation, and related complications; including: pheresis and cell preparation/storage; marrow ablative therapy; drugs, supplies, hospitalization with outpatient follow-up; medical/surgical, diagnostic, emergency, and rehabilitative services; and the number of days of pre- and posttransplant care in the global definition

    Provider Actions, Authorization, and Documentation

    Prior Authorization

    Prior authorization required for DLI and listed procedure codes

    Prior authorization is required for donor lymphocyte infusion (DLI) procedures and related billing codes. Providers must submit clinical rationale and supporting documentation demonstrating prior allogeneic HSCT and evidence of relapse risk or active relapse when requesting authorization for codes such as 38242 (Allogeneic lymphocyte infusions), 38215, 86950, and S2150.

    • Submit documentation of prior allogeneic HSCT and indication (relapsed/refractory hematologic malignancy or risk of relapse).
    • Include relevant chimerism data and evidence of mixed chimerism when applicable.
    Note

    Coverage subject to member contract and regulatory requirements

    Coverage and authorization decisions are determined by the member's coverage documents and applicable state and federal requirements. Providers should review applicable NCDs/LCDs and state Medicaid manuals before applying criteria.

    • Coverage is subject to terms, conditions, exclusions, and limitations of the member's evidence of coverage or policy.
    • State Medicaid provisions take precedence where they conflict with this clinical policy; review the state Medicaid manual for specific guidance.
    Step Therapy

    Document prior/adjunct chemotherapy when DLI is used for relapsed AML

    When DLI is used for relapsed AML, it is often combined with chemotherapy; documentation of prior or concurrent adjunct therapies may be relevant to authorization decisions.

    • Provide records of recent or planned chemotherapy regimens when DLI is proposed for relapsed AML.
    • Detail timing and rationale for combining DLI with adjunct systemic therapy.
    Note

    No additional provider action noted

    (No additional provider-action specified in the source.)

    Documentation Required

    Required clinical documentation to support authorization

    Prior authorization requests and claims should include documentation supporting prior allogeneic HSCT, the clinical indication (relapsed/refractory hematologic malignancy or high risk of relapse/mixed chimerism with relapse risk), chimerism status, and absence of contraindications such as grade ≥2 acute GvHD.

    • Include prior HSCT records, pathology/hematology reports, and chimerism testing results.
    • Explicitly document absence of grade 2 or higher acute graft-versus-host disease prior to DLI.
    Billing Rule

    Follow Health Plan administrative policies and coverage terms

    Follow the Health Plan's administrative policies, procedures, and the terms of the member's coverage documents when submitting claims; this clinical policy is a guide to medical necessity and is not a guarantee of payment.

    • Ensure claim submission follows Health Plan-level administrative rules and coding guidance.
    • Review the clinical policy for medical necessity criteria but verify payment under the member's contract.
    Denial Risk

    Unsupported indications may be denied

    Do not request authorization or perform DLI for indications not supported by this policy; use of DLI for indications other than post-allogeneic HSCT to treat relapsed/refractory hematologic malignancy or to decrease relapse risk (including genetic modification or ex vivo manipulation of donor lymphocytes) is not supported and may be denied.

    • Genetic modification or ex vivo manipulation of donor lymphocytes is not supported outside of a clinical trial.
    • Requests for DLI outside the post-allogeneic HSCT indications may be denied.
    Denial Risk

    Do not perform DLI for active grade ≥2 acute GvHD

    DLI performed in the presence of grade 2 or higher acute graft-versus-host disease (GvHD) is a contraindication and is not supported; such requests may be denied.

    • Document absence of grade ≥2 acute GvHD before authorization; presence of grade ≥2 acute GvHD should preclude DLI.
    • Grade 2 or higher acute GvHD at the time of proposed infusion is a basis for denial.
    Note

    State Medicaid provisions take precedence when conflicting

    If state Medicaid provisions conflict with this clinical policy, the state Medicaid manual governs; providers must follow applicable state Medicaid requirements when treating Medicaid members.

    • Review the state Medicaid manual for any provisions that supersede this clinical policy.
    • Ensure compliance with Medicaid-specific coverage rules when they differ from this policy.

    Definitions and Key Terms

    Mixed chimerism — definition
    TermMixed chimerism
    DefinitionDetection of less than 90% donor cells after HSCT.
    Clinical relevanceMay indicate incomplete hematopoietic engraftment and increased risk of relapse; conversion to full chimerism can be an indication for DLI when relapse risk exists.
    Full (complete) chimerism — definition
    TermFull (complete) chimerism
    DefinitionDetection of 100% donor cells after HSCT.
    Clinical relevanceSuggests complete hematopoietic replacement; DLI is not recommended solely to increase donor chimerism in patients who already have full chimerism.
    Health Plan — definition
    TermHealth Plan
    DefinitionA health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan's affiliates.
    Policy roleThis clinical policy is a guide to medical necessity and does not constitute a contract or guarantee of payment; coverage decisions remain subject to the member's coverage documents and applicable laws.

    Background on Donor Lymphocyte Infusion (DLI)

    Donor lymphocyte infusion (DLI) is the infusion of donor mononuclear lymphocytes after allogeneic hematopoietic stem cell transplantation (HSCT) intended to induce a graft‑versus‑tumor effect, reduce relapse risk, or convert mixed donor chimerism to full donor chimerism when clinically warranted. DLI has demonstrated high remission rates in chronic myeloid leukemia (CML), more limited effectiveness in acute leukemias, and potential activity in other hematologic malignancies. Major complications include graft‑versus‑host disease (GvHD) and, less commonly, bone marrow aplasia; these risks should be weighed against potential benefit when considering DLI.

    Key Statistics

    40-60%approximate incidence of GvHD after DLI
    70-80%complete remission rate for relapsed CML after DLI
    2-5%incidence of bone marrow aplasia after DLI
    2016copyright year
    Policy Summary
    Payermhn
    PolicyDonor Lymphocyte Infusion
    Policy CodePolicy CP.MP.101
    Change TypeNo material changes noted
    Effective Date
    Next Review Date
    Key ActionObtain prior authorization and submit clinical rationale with documentation of prior allogeneic HSCT and indication (relapse or high relapse risk).
    SourceLink
    On This Page
    Coverage Criteria for Donor Lymphocyte Infusion (DLI)Regimens and Indications CoveredProcedure and Billing CodesProvider Actions, Authorization, and DocumentationDefinitions and Key TermsBackground on Donor Lymphocyte Infusion (DLI)Key Statistics

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.